Growth Factor Inhibitors

Overview of Cancer Therapeutics

  • Focus on the classes of targeted therapies: These therapies are designed to target the specific mechanisms that allow cancer cells to grow and divide, rather than using traditional methods like chemotherapy that affect all rapidly dividing cells.

  • Importance of growth factor inhibitors in cancer treatment: These drugs can block signals that promote cancer cell growth, making them a vital part of modern cancer therapy.

Growth Factor Inhibitors

  • Definition: Class of drugs that inhibit signaling pathways activated by growth factors bound to their respective receptors on cancer cells. Growth factors are proteins that can promote cell division and growth, which is why blocking their action can help halt the progression of cancer.

Importance of Growth Factors

  • Growth factors are essential for cell division and proliferation: Normal cells require these signals to grow, but cancer cells can abuse them to become uncontrollable.

  • Cancer cells exploit these pathways for growth, making them a target for therapy: By understanding how cancer cells hijack these signals, researchers can develop drugs that specifically disrupt these growth-related pathways.

  • Reference to the first hallmark of cancer: self-sufficiency in growth signals: This means that cancer cells can produce the signals they need to grow independently, unlike normal cells that rely on outside signals.

Key Receptors in Cancer

  1. Epidermal Growth Factor Receptor (EGFR)

    • Critical in many cancers, especially non-small cell lung cancer: When EGFR is overly active, it can lead to increased growth and division of cancerous cells.

  2. Human Epidermal Growth Factor Receptor 2 (HER2)

    • Originally identified as HER2/NEU from a neural tumor cell line: HER2 is involved in breast cancer and is a common target for specific therapies to inhibit its activity.

  3. Platelet-Derived Growth Factor Receptor (PDGFR)

    • Important for mesenchymal cell signaling and cancer cell proliferation: PDGFR plays a role in how cells communicate and grow together, and its inhibition can slow tumor growth.

Mechanism of Action of EGFR and Related Therapies

  • Binding of epidermal growth factor (EGF) to EGFR promotes a signaling cascade leading to cell division: This is how normal cells receive signals to grow.

  • Dimerization of EGFR is essential for activation:

    • Two EGFR molecules bind EGF, undergo conformational change, and come together to form a dimer: This interaction is critical for the signaling process to start.

    • Intracellular kinase domains become activated, leading to autophosphorylation, which activates downstream signaling affecting growth genes: This means that once EGFR is activated, it can transmit signals that tell the cell to grow and divide.

Crosstalk in Signaling Pathways

  • Crosstalk: Interaction between different signaling pathways (e.g., EGFR activating PI3-kinase via RAS): This concept means that different pathways can influence each other, which can complicate treatment since disrupting one pathway might not be enough to stop cancer growth if others are still active.

EGFR Inhibitors
1. Antibody-Based Inhibitors

  • Definition: Monoclonal antibodies that block the binding of ligands to EGFR: These are engineered proteins that can specifically bind to EGFR and block its function.

  • Example: Cetuximab (marketed as Erbitux)

    • Binds to extracellular domain 3 of EGFR, blocking ligand binding: By preventing EGFR from receiving growth signals, this drug effectively starves the cancer cells.

    • Triggers Antibody-Dependent Cell Mediated Cytotoxicity (ADCC): This means that the body's immune system is alerted to the presence of the cancer cells and can help destroy them.

    • Usage in clinical practice:

      • Administered via IV, with a loading dose followed by weekly doses: This is how the treatment is delivered to patients.

      • Primarily used in colon cancer and head and neck cancers: The effectiveness of cetuximab has been specifically noted in these types of cancer.

      • Efficacy in wild-type KRAS tumors in colon cancer and radiation in head and neck carcinoma: Specific genetic backgrounds determine how well the treatment works.

2. Tyrosine Kinase Inhibitors (TKIs)

  • Definition: Drugs that inhibit the activity of tyrosine kinases involved in EGFR signaling: These are small molecules that interfere with the pathways inside the cell that lead to growth signals being acted upon.

  • Examples:

    • Erlotinib and Gefitinib: Competitive inhibitors of ATP binding to EGFR: They block the energy source needed for EGFR to activate signaling pathways.

    • Afatinib: Non-competitive inhibitor: This means it works differently by binding to EGFR and preventing activation without competing for the same binding site.

    • Osimertinib: Designed specifically to target the T790M mutation in EGFR, developed after resistance to erlotinib and gefitinib: This drug is targeted at a specific mutation that is commonly associated with resistance to other drugs.

  • Clinical applications:

    • Used mainly in non-small cell lung cancer with mutant EGFR: The presence of specific mutations in the EGFR gene guides the use of these medications.

    • Administered orally; common side effects include rash and diarrhea (>20% incidence): Understanding side effects helps prepare patients for their treatment plans.

    • Notable drug interactions with CYP3A4 and proton pump inhibitors (PPIs): These interactions can affect how the drug works or cause additional side effects.

HER2 Inhibitors
Mechanism of Action

  • HER2: Exists in a constitutively active state without ligand binding, mainly involved in breast cancer when overexpressed: This means that some cancer cells may amplify this receptor, causing uncontrolled growth even in the absence of the usual growth signals.

  • Therapeutic Target: Trastuzumab

    • Works by inhibiting dimerization, enhancing ADCC effects: This drug blocks HER2 from partnering with other receptors, which can help reduce cancer cell proliferation.

  • Side Effects:

    • Associated with cardiotoxicity, especially when combined with doxorubicin (20% incidence): Patients need to be monitored for heart-related side effects, especially if they are taking multiple medications.

Other HER2 Inhibitors

  • Lapatinib: A more unselective TKI that inhibits both HER2 and EGFR: This drug is important for targeting multiple growth factor pathways to maximize treatment efficacy.

    • Administered orally, often in combination with trastuzumab after loss of response: This celebrates the importance of combination therapy to maintain cancer control.

PDGFR Inhibitors
Mechanism and Targeting

  • PDGFR: Primarily involved in mesenchymal signaling, expresses high levels in certain cancers: Targeting this receptor can hinder the cancer cells’ ability to grow and spread, especially in tumors that are reliant on this pathway.

  • Key Drugs:

    • Olaratinib: Blocks ligand binding: By preventing growth signals from binding, this drug can reduce tumor growth.

    • Imatinib: Inhibits kinase activity of PDGFR: This drug interrupts the signaling pathways that allow cancers to thrive.

Drug Combination Strategies

  • Since many cancer cells overexpress multiple receptors, combination therapy becomes crucial to inhibit all parallel signaling pathways to avoid crosstalk effects: Using multiple drugs can help ensure that all possible growth signals are blocked, which is more effective than targeting a single pathway.

  • Downstream Targeting: Working further downstream can inhibit multiple receptors simultaneously (e.g., targeting AKT activation): This strategy allows for broader treatment coverage, addressing several pathways involved in tumor growth.

Summary of Inhibitors and Clinical Examples

  • Students are responsible for knowing all mentioned inhibitors and their usage context in therapies for specific cancer types: Familiarity with these details helps prepare for class discussions and exams.

  • Preparation for homework and exams should include the mechanisms, side effects, and combinations used in therapeutic scenarios for each receptor class: Understanding the underlying science and treatment implications is crucial for mastering the subject.